Ugeskrift for laeger
-
Ugeskrift for laeger · Jan 2006
[Length of stay after primary total hip and knee arthroplasty in Denmark, 2001-2003].
We studied length of stay (LOS) after operation with total hip arthroplasty (THA) and total knee arthroplasty (TKA) in Denmark from 2001 to 2003 to determine whether experiences from published accelerated tracks had been implemented in Denmark, resulting in reduced LOS. ⋯ The LOS shows that accelerated tracks - with accompanying shorter LOS in the area of 4 to 6 days - have not been implemented on a nationwide basis, and we find a need to review the principles for rehabilitation after operation with THA and TKA in the direction of accelerated tracks. This could be expected not only to generate large savings in LOS but also to reduce the need for rehabilitation and possibly reduce morbidity.
-
Ugeskrift for laeger · Jan 2006
Case Reports[Pediatric septic shock--timing, volume resuscitation and anticoagulation therapy].
Pediatric septic shock is associated with severe hypovolemia, and children frequently respond well to aggressive volume resuscitation. In recent years, improved outcome has been reported when aggressive volume resuscitation and goal-directed therapies were applied to children with septic shock. We report a case of severe meningococcal septic shock in a child aged 16 months where aggressive volume resuscitation and anticoagulation therapy were applied.
-
The unprecedented spread of the highly pathogenic avian influenza type A H5N1 is a threat to veterinary public health. However, the virus does not in its present form constitute a major threat to human public health. ⋯ It is not possible to predict if this will happen, when it may happen or how serious it may be. At present, seasonal influenza represents the greatest burden of illness among the three types of influenza A illness: seasonal, avian, and pandemic influenza.
-
Acceptable adverse effects and a clinical relevant weight loss of 3 to 5 kilograms have been found in long-term randomized clinical trials for sibutramine (Reductil) and orlistat (Xenical); these drugs may be prescribed for treatment of obesity for a duration of one and four years, respectively. This also seems to be the case for rimonabant (Acomplia), which is expected to receive approval in 2005 or 2006. However, until data on morbidity and mortality are available from RCTs, there is no absolute indication for prescribing drugs for treatment of obesity.